Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Understanding Poor Vaccine Responses to Hepatitis B Vaccination
NCT04674462Phase 4Active, not recruiting
- Sponsor
- NYU Langone Health
- Start
- Jul 2022
- Primary completion
- Jun 2026
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
A Phase 4 trial of Heplisav-B in hepatitis B (HBV), sponsored by NYU Langone Health. Started Jul 2022; status: active, not recruiting.
02
Drugs
Heplisav-B
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04674462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674462.